Lipid rafts and redox regulation of cellular signaling in cholesterol induced atherosclerosis

Current Cardiology Reviews

Volumn 6, Issue 4, 2010, Pages 309-324

  Catalgol, Betul ^a   Ozer, Nesrin Kartal ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Hypercholesterolemia; Lipid rafts; Reactive species; Redox regulation; Signaling

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; LIPOXYGENASE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; XANTHINE OXIDASE;

ARTICLE; ATHEROSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID RAFT; MEDICAL LITERATURE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 78651269900     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310793566181     Document Type: Article

References (183)

1. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84(4): 1381-478.
2. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. PhysiolRev 2003; 83(4): 1069-112.
3. Schmitz G, Grandl M. Role of redox regulation and lipid rafts inmacrophages during Ox-LDL mediated foam cell formation. AntioxidRedox Signal 2007; 9(9): 1499-518.
4. Steinberg D. The LDL modification hypothesis of atherogenesis:an update. J Lipid Res 2009; 50: S376-S381.
5. Stocker R, Keaney JF Jr. New insights on oxidative stress in theartery wall. J Thromb Haemost 2005; 3: 1825-34.
6. Channon KM, Guzik TJ. Mechanisms of superoxide production inhuman blood vessels: relationship to endothelial dysfunction, clinicaland genetic risk factors. J Physiol Pharmacol 2002; 53(4): 515-24.
7. Pongnimitprasert N. Atherosclerosis and NADPH Oxidase. SilpakornU Sci Tech J 2009; 3(1): 13-24.
8. Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis ofatherosclerosis: enzymatic transformation of human low densitylipoprotein to an atherogenic moiety. J Exp Med 1995; 182(6): 1959-71.
9. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
10. Seifert PS, Hugo F, Tranum-Jensen J, Zâhringer U, Muhly M, Bhakdi S. Isolation and characterization of a complementactivatinglipid extracted from human atherosclerotic lesions. J ExpMed 1990; 172(2): 547-57.
11. Parthasarathy S, Barnett J. Phospholipase A2 activity of low densitylipoprotein: evidence for an intrinsic phospholipase A2 activityof apoprotein B-100. Proc Natl Acad Sci USA 1990; 87(24): 9741-5.
12. Tjoelker LW, Eberhardt C, Unger J, et al. Plasma plateletactivatingfactor acetylhydrolase is a secreted phospholipase A2with a catalytic triad. J Biol Chem 1995; 270(43): 25481-7.
13. Tao N, Wagner SJ, Lublin DM. CD36 is palmitoylated on both NandC-terminal cytoplasmic tails. J Biol Chem 1996; 271: 22315-20.
14. Nordberg J, Arnér ES. Reactive oxygen species, antioxidants, andthe mammalian thioredoxin system. Free Radic Biol Med 2001; 31(11): 1287-312.
15. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Poulsen H, Verhagen H, Astley SB. Biomarkers, Mol Aspects Med 2002; 23 (1-3): 101-208.
16. Catalgol B, Grune T. Protein pool maintenance during oxidativestress. Curr Pharm Des 2009; 15(26): 3043-51.
17. Samuel SM, Thirunavukkarasu M, Maulik N. Methods to Detect inVitro and in Vivo Angiogenesis: Approach and Protocols. In: DipakDas, Ed. Methods in Redox Signaling. Mary Ann Liebert 2010; pp. 180-190.
18. Ahsan MK, Nakamura H, Yodoi J. Redox Regulation by Thioredoxinin Cardiovascular Diseases. In: Dipak K. D. Ed. Methods inRedox Signaling. Mary Ann Liebert 2010; pp. 159-65.
19. Fortuno A, Jose GS, Moreno MU, Diez J, Zalba G. Oxidative stressand vascular remodelling. Exp Physiol 2005; 90: 457-62.
20. Micie DD. Insulin resistance and atherosclerosis. Jugoslov MedBiochem 2006; 25(4): 343-8.
21. Vogiatzi G, Tousoulis D, Stefanadis C. The role of oxidative stressin atherosclerosis. Hellenic J Cardiol 2009; 50(5): 402-9.
22. Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized lowdensitylipoprotein-induced apoptosis. Biochim Biophys Acta 2002; 1585(2-3): 213-21.
23. Cathcart MK. Regulation of superoxide anion production byNADPH oxidase in monocytes/macrophages contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 23-8.
24. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein byChlamydia pneumoniae. J Infect Dis 1999; 180: 780-90.
25. Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O. Scavenger receptor class B type I as a receptor for oxidizedlow density lipoprotein. J Lipid Res 2001; 42(9): 1474-82.
26. Sigari F, Lee C, Witztum JL, Reaven PD. Fibroblasts that overexpress15-lipoxygenase generate bioactive and minimally modifiedLDL. Arterioscler Thromb Vasc Biol. 1997; 17(12): 3639-45.
27. Kritharides L, Jessup W, Gifford J, Dean RT. A method for definingthe stages of low-density lipoprotein oxidation by the separationof cholesterol- and cholesteryl ester-oxidation products usingHPLC. Anal Biochem 1993; 213(1): 79-89.
28. Leonarduzzi G, Sottero B, Poli G. Oxidized products of cholesterol:dietary and metabolic origin, and proatherosclerotic effects(review). J Nutr Biochem 2002; 13(12): 700-10.
29. Schnackenberg CG. Physiological and pathophysiological roles ofoxygen radicals in the renal microvasculature. Am J Physiol RegulIntegr Comp Physiol 2002; 282: R335-R342.
30. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Science 2005; 109: 217-26.
31. Dworakowski R, Anilkumar N, Zhang M, Shah AM. Redox signallinginvolving NADPH oxidasederived reactive oxygen species. Biochem Soc Trans 2006; 34: 960-4.
32. Chen YR, Chen CL, Zhang L, Green-Church KB, Zweier JL. Superoxidegeneration from mitochondrial NADH dehydrogenase inducesself-inactivation with specific protein radical formation. JBiol Chem 2005; 280(45): 37339-48.
33. Zmijewski JW, Landar A, Watanabe N, Dickinson DA, Noguchi N, Darley-Usmar VM. Cell signaling by oxidized lipids and the role ofreactive oxygen species in the endothelium. Biochem Soc Trans 2005; 33: 1385-9.
34. Humphries KM, Szweda LI. Selective inactivation of alphaketoglutaratedehydrogenase and pyruvate dehydrogenase: reactionof lipoic acid with 4-hydroxy-2-nonenal. Biochemistry 1998; 37(45): 15835-41.
35. Humphries KM, Yoo Y, Szweda LI. Inhibition of NADH-linkedmitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 1998; 37(2): 552-7.
36. Antoniades C, Tousoulis D, Marinou K, Stefanadi E, Ntarladimas I, Latsios G, Konniari K, Papageorgiou N, Siasos G, Stefanadis C. Effects of lipid profile on forearm hyperemic response in youngsubjects. Hellenic J Cardiol 2006; 47: 152-7.
37. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschläger N, Hornig B, Drexler H, Harrison DG. Electron spin resonance characterization of vascular xanthine, oxidaseactivity in patients with coronary artery disease NAD(P)H. relationto endothelium-dependent vasolidation. Circulation 2003; 107: 1383-9.
38. Li JM, Shah AM. ROS generation by nonphagocytic NADPHoxidase: Potential relevance in diabetes nephropathy. J Am SocNephrol 2003; 14: S221-S226.
39. Jin S, Yi F, Li PL. Contribution of lysosomal vesicles to the formationof lipid raft redox signaling platforms in endothelial cells. AntioxidRedox Signal. 2007; 9(9): 1417-26.
40. Park JY, Ferrell RE, Park JJ, Hagberg JM, Phares DA, Jones JM, Brown MD. NADPH oxidase p22phox gene variants are associatedwith systemic oxidative stress biomarker responses to exercisetraining. J Appl Physiol 2005; 99: 1905-11.
41. Bokoch GM, Dieboid BA. Current molecular models for NADPHoxidase regulation by Rac GTPase. Blood 2002; 100(8): 2692-6.
42. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologsof gp91phox: cloning and tissue expression of Nox3, Nox4, andNox5. Gene 2001; 269: 131-40.
43. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, and Busse R. A gp91phox containing NADPH oxidase selectively expressedin endothelial cells is a major source of oxygen radicalgeneration in the arterial wall. Circ Res 2000; 87: 26-32.
44. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M. Nox4 as the majorcatalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227-33.
45. O'Donnell VB, Freeman BA. Interactions between nitric oxide andlipid oxidation pathways: implications for vascular disease. CircRes 2001; 88(1): 12-21.
46. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxidesynthase is present within human atherosclerotic lesions and promotesthe formation and activity of peroxynitrite. Lab Invest 1996; 75(1): 77-85.
47. Vepa S, Scribner WM, Parinandi NL, English D, Garcia JG, Natarajan V. Hydrogen peroxide stimulates tyrosine phosphorylation offocal adhesion kinase in vascular endothelial cells. Am J Physiol 1999; 277: L150-8.
48. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase producthypochlorous acid oxidizes HDL in the human artery wall and impairsABCA-1 dependent cholesterol transport. Proc Natl Acad SciUSA 2004; 114: 529-41.
49. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in humanatherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
50. Pennathur S, Bergt C, Shao B, et al. Human atherosclerotic intimaand blood of patients with established coronary artery disease containHDL damaged by reactive nitrogen species. J Biol Chem 2004; 279: 42977-83.
51. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. Therole of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11: 155-61.
52. Shao B, Oda MN, Bergt C, Fu X, Green PS, Brot N, Oram JF, Heinecke JW. Myeloperoxidase impairs ABCA1-dependent cholesterolefflux through methionine oxidation and site-specific tyrosinechlorination of apolipoprotein A-I. J Biol Chem 2006; 281: 9001-4.
53. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocytemacrophage colony-stimulating factor in human atherosclerosis andimplications in acute coronary syndromes. Am J Pathol 2001; 158: 879-91.
54. Francis GA, Oram JF, Heinecke JW, and Bierman EL. Oxidativetyrosylation of HDL enhances the depletion of cellular cholesterylesters by a mechanism independent of passive sterol desorption. Biochemistry 1996; 35: 15188-97.
55. Francis GA, Mendez AJ, Bierman EL, and Heinecke JW. Oxidativetyrosylation of high density lipoprotein by peroxidase enhancescholesterol removal from cultured fibroblasts and macrophagefoam cells. Proc Natl Acad Sci U S A 1993; 90: 6631-5.
56. Macdonald DL, Terry TL, Agellon LB, Nation PN, Francis GA. Administration of tyrosyl radicaloxidized HDL inhibits the developmentof atherosclerosis in apolipoprotein E-deficient mice. ArteriosclerThromb Vasc Biol 2003; 23: 1583-8.
57. Tousoulis D, Böger RH, Antoniades C, Siasos G, Stefanadi E, Stefanadis C. Mechanisms of disease: Larginine in coronary atherosclerosis-a clinical perspective. Nat Clin Pract Cardiovasc Med 2007; 4: 274-83.
58. Dusting GJ, Selemidis S, Jiang F. Mechanism for suppressingNADPH oxidase in the vascular wall. Mem Inst Oswaldo Cruz, Riode Janeiro 2005; 100 (Suppl. 1): 97-103.
59. Ruef J, Hu ZY, Yin LY, Wu Y, Hanson SR, Kelly AB, Harker LA, Rao GN, Runge MS, Patterson C. Induction of vascular endothelialgrowth factor in balloon-injured baboon arteries. A novel role forreactive oxygen species in atherosclerosis. Circ Res 1997; 1: 24-33.
60. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1005-L1028.
61. Das DK. Redox regulation of cardiomyocyte survival and death. Antioxid Redox Signal 2001; 3: 23-37.
62. Harizi H and Gualde N. Pivotal role of PGE2 and IL-10 in thecross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol 2006; 3: 271-7.
63. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage:complexity in action. Trends Cell Biol 2004; 14: 628-38.
64. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity andinflammation. Curr Opin Immunol 2006; 18: 39-48.
65. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis ofatherosclerosis. J Atheroscler Thromb 2003; 10: 63-71.
66. Robbesyn F, Salvayre R, Negre-Salvayre A. Dual role of oxidizedLDL on the NF-kappaB signaling pathway. Free Radic Res 2004; 38(6): 541-51.
67. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, Osawa T. Activation of stress signaling pathways by the end product of lipidperoxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellularperoxide production. J Biol Chem 1999; 274: 2234-42.
68. Leonarduzzi G, Chiarpotto E, Biasi F, Poli G. 4-Hydroxynonenaland cholesterol oxidation products in atherosclerosis. Mol NutrFood Res 2005; 49: 1044-9.
69. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessaryfor macrophage foam cell formation. Cell Metab 2006; 4: 211-21.
70. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer M, Akhmedov A. Requirement of JNK2 for scavenger receptor A-mediated foamcell formation in atherogenesis. Science 2004; 306: 1558-61.
71. Chen K, Febbraio M, Li W, Silverstein RL. A specific CD36-dependent signaling pathway is required for platelet activation byoxidized low-density lipoprotein. Circ Res 2008; 102: 1512-9.
72. Feng J, Han J, Pearce SFA, Silverstein RL, Gotto AM, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL andIL-4 by a common signaling pathway dependent on protein kinaseC and PPAR-gamma. J Lipid Res 2000; 41: 688-96.
73. Ricciarelli R, Zingg JM, Azzi A. Vitamin E reduces the uptake ofoxidized LDL by inhibiting CD36 scavenger receptor expression incultured aortic smooth muscle cells. Circulation 2000; 102(1): 82-7.
74. Sirikçi O, Ozer NK, Azzi A. Dietary cholesterol-induced changesof protein kinase C and the effect of vitamin E in rabbit aorticsmooth muscle cells. Atherosclerosis 1996; 126(2): 253-63.
75. Ozer NK, Sirikçi O, Taha S, San T, Moser U, Azzi A. Effect ofvitamin E and probucol on dietary cholesterol-induced atherosclerosisin rabbits. Free Radic Biol Med 1998; 24(2): 226-33.
76. Ozer NK, Negis Y, Aytan N, Villacorta L, Ricciarelli R, Zingg JM, Azzi A. Vitamin E inhibits CD36 scavenger receptor expression inhypercholesterolemic rabbits. Atherosclerosis 2006; 184(1): 15-20.
77. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, and Evans RM. PPAR-gamma dependent and independent effects on macrophagegene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52.
78. Teissier E, Nohara A, Chinetti G, Paumelle R, Cariou B, Fruchart JC, Brandes RP, Shah A, Staels B. Peroxisome proliferatoractivatedreceptor alpha induces NADPH oxidase activity inmacrophages, leading to the generation of LDL with PPAR-alphaactivation properties. Circ Res 2004; 95: 1174-82.
79. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisomeproliferator-activated receptor gamma (PPARgamma) in humanatherosclerosis and regulation in macrophages by colony stimulatingfactors and oxidized low density lipoprotein. Proc Natl AcadSci SA 1998; 95: 7614-9.
80. Tontonoz P, Nagy L. Regulation of macrophage gene expressionby peroxisome-proliferator-activated receptor gamma: implicationsfor cardiovascular disease. Curr Opin Lipidol 1999; 10: 485-90.
81. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. 27-Hydroxycholesterol is an endogenousligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001; 276: 38378-87.
82. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. OxidizedLDL regulates macrophage gene expression through ligand activationof PPARgamma. Cell 1998; 93: 229-40.
83. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, and Glass CK. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by12/15-lipoxygenase. Nature 1999; 400: 378-82.
84. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, and Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995; 83: 813-9.
85. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophagesin human atheroma contain PPARgamma: differentiationdependentperoxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activitythrough PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998a; 153: 17-23.
86. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisomeproliferator-activated receptor gamma activators inhibit gene expressionand migration in human vascular smooth muscle cells. Circ Res 1998b; 83: 1097-103.
87. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit productionof monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
88. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, and Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesionmacrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101: 2411-7.
89. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellularcholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000; 97: 12097-102.
90. Silverstein RL, Febbraio M. CD36 and atherosclerosis. Curr OpinLipidol 2000; 11: 483-91.
91. Zhao M, Liu Y, Wang X, New L, Han J, Brunk UT. Activation ofthe p38MAPkinase pathway is required for foam cell formationfrom macrophages exposed to oxidized LDL. APMIS 2002; 110: 458-68.
92. Leonarduzzi G, Gamba P, Gargiulo S, et al. Oxidation as a crucialreaction for cholesterol to induce tissue degeneration: CD36 overexpressionin human promonocytic cells treated with a biologicallyrelevant oxysterol mixture. Aging Cell 2008; 7(3): 375-82.
93. Hara H, Yokoyama S. Interaction of free apolipoproteins withmacrophages: formation of high density lipoprotein-like lipoproteinsand reduction of cellular cholesterol. J Biol Chem 1991; 266: 3080-6.
94. Takahashi K, Takeya M, Sakashita N. Multifunctional roles ofmacrophages in the development and progression of atherosclerosisin humans and experimental animals. Med Electron Microsc 2002; 35: 179-203.
95. Diederich W, Orso E, Drobnik W, and Schmitz G. ApolipoproteinAI and HDL(3) inhibit spreading of primary human monocytesthrough a mechanism that involves cholesterol depletion and regulationof CDC42. Atherosclerosis 2001; 159: 313-24.
96. Schmitz G, Buechler C. ABCA1: regulation, trafficking and associationwith heteromeric proteins. Ann Med 2002; 34: 334-47.
97. Zmijewski JW, Moellering DR, Le Goffe C, Landar A, Ramachandran A, Darley-Usmar VM. Oxidized LDL induces mitochondriallyassociated reactive oxygen/nitrogen species formationin endothelial cells. Am J Physiol Heart Circ Physiol 2005; 289: H852-H861.
98. Balla J, Jacob HS, Balla G, Nath K, Eaton JW, Vercellotti GM. Endothelial-cell heme uptake from heme proteins: induction of sensitizationand desensitization to oxidant damage. Proc Natl AcadSci USA 1993; 90: 9285-9.
99. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC. Heme as keyregulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol Ther 2006; 111: 327-45.
100. Miller YI, Altamentova SM, Shaklai N. Oxidation of low-densitylipoprotein by hemoglobin stems from a heme-initiated globin radical:antioxidant role of haptoglobin. Biochemistry 1997; 36: 12189-98.
101. Tabas I. Apoptosis and plaque destabilization in atherosclerosis:the role of macrophage apoptosis induced by cholesterol. CellDeath Differ 2004; 11 (Suppl 1): S12-6.
102. Nakamura H, Bai J, Nishinaka Y, et al. Expression of thioredoxinand glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000; 24: 53-60.
103. Okuda M, Inoue N, Azumi H, et al. Expression of glutaredoxin inhuman coronary arteries: its potential role in antioxidant protectionagainst atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1483-7.
104. Miwa K, Kishimoto C, Nakamura H, et al. Serum thioredoxin andalpha-tocopherol concentrations in patients with major risk factors. Circ J 2005; 69: 291-4.
105. Sun J, Steenbergen C, Murphy E. S-nitrosylation: NO-related redoxsignaling to protect against oxidative stress. Antioxid Redox Signal 2006; 8: 1693-1705.
106. Arner ES, Holmgren A. Physiological functions of thioredoxin andthioredoxin reductase. Eur J Biochem 2000; 267: 6102-9.
107. Furman C, Rundlof AK, Larigauderie G, et al. Thioredoxin reductase1 is upregulated in atherosclerotic plaques: specific inductionof the promoter in human macrophages by oxidized low-densitylipoproteins. Free Radic Biol Med 2004; 37: 71-85.
108. Conway JP, Kinter M. Dual role of peroxiredoxin I in macrophagederivedfoam cells. J Biol Chem 2006; 281: 27991-8001.
109. Wang Y, Qiao M, Mieyal JJ, Asmis LM, Asmis R. Molecularmechanism of glutathione-mediated protection from oxidized lowdensitylipoprotein-induced cell injury in human macrophages: roleof glutathione reductase and glutaredoxin. Free Radic Biol Med 2006; 41: 775-85.
110. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR. Serum glutathione in adolescent males predicts parentalcoronary heart disease. Circulation 1999; 100: 2244-7.
111. Shioji K, Nakamura H, Masutani H, Yodoi J. Redox regulation bythioredoxin in cardiovascular diseases. Antioxid Redox Signal 2003; 5: 795-802.
112. Shen L, Sevanian A. OxLDL induces macrophage gamma-GCSHSprotein expression: a role for oxLDL-associated lipid hydroperoxidein GSH synthesis. J Lipid Res 2001; 42: 813-23.
113. Darley-Usmar VM, Severn A, O'Leary VJ, and Rogers M. Treatmentof macrophages with oxidized low-density lipoprotein increasestheir intracellular glutathione content. Biochem J 1991; 278: 429-34.
114. Hagg D, Englund MC, Jernas M, et al. Oxidized LDL induces acoordinated up-regulation of the glutathione and thioredoxin systemsin human macrophages. Atherosclerosis 2006; 185: 282-9.
115. Gotoh N, Graham A, Nikl E, and Darley-Usmar VM. Inhibition ofglutathione synthesis increases the toxicity of oxidized low-densitylipoprotein to human monocytes and macrophages. Biochem J 1993; 296: 151-4.
116. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-72.
117. Das DK. Redox Signaling via Lipid Rafts. In: Dipak Das, Ed. Methods in Redox Signaling. Mary Ann Liebert 2010; pp. 156-158.
118. Kabouridis PS. Lipid rafts in T cell receptor signalling. Mol MembrBiol 2006; 23: 49-57.
119. Simons K, Toomre D. Lipid rafts and signal transduction. Nat RevMol Cell Biol 2000; 1: 31-9.
120. Grassme H, Jendrossek V, Bock J, Riehle A, Gulbins E. Ceramiderichmembrane rafts mediate CD40 clustering. J Immunol 2002; 168: 298-307.
121. Zhang AY, Yi F, Zhang G, Gulbins E, Li PL. Lipid raft clusteringand redox signaling platform formation in coronary arterial endothelialcells. Hypertension 2006; 47: 74-80.
122. Li PL, Zhang Y, Yi F. Lipid raft redox signaling platforms in endothelialdysfunction. Antioxid Redox Signal 2007; 9: 1457-70.
123. Magee AI, Parmryd I. Detergent-resistant membranes and the proteincomposition of lipid rafts. Genome Biol 2003; 4: 234.
124. Tillman TS, Cascio M. Effects of membrane lipids on ion channelstructure and function. Cell Biochem Biophys 2003; 38: 161-90.
125. Gulbins E, Li PL. Physiological and pathophysiological aspects ofceramide. Am J Physiol Regul Integr Comp Physiol 2006; 290: R11-R26.
126. Parton RG. Caveolae and caveolins. Curr Opin Cell Biol 1996; 8: 542-8.
127. Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membranedomains. Biochim Biophys Acta 2005; 1746: 284-94.
128. Kolesnick RN, Kronke M. Regulation of ceramide production andapoptosis. Annu Rev Physiol 1998; 60: 643-65.
129. Gulbins E, Grassme H. Ceramide and cell death receptor clustering. Biochim Biophys Acta 2002; 1585: 139-45.
130. Grassme H, Jekle A, Riehle A, et al. CD95 signaling via ceramiderichmembrane rafts. J Biol Chem 2001; 276: 20589-96.
131. Simons K, Ikonen E. How cells handle cholesterol. Science 2000; 290: 1721-1726.
132. Lotocki G, Alonso OF, Dietrich WD, Keane RW. Tumor necrosisfactor receptor 1 and its signaling intermediates are recruited tolipid rafts in the traumatized brain. J Neurosci 2004; 24: 11010-6.
133. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998; 14: 111-36.
134. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipidrafts in B cell antigen receptor signaling and antigen targeting. JExp Med 1999; 190: 1549-60.
135. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene 2003; 22: 7070-7.
136. Hoekstra D, Maier O, van der Wouden JM, Slimane TA, van ISC. Membrane dynamics and cell polarity: the role of sphingolipids. JLipid Res 2003; 44: 869-77.
137. Kinscherf R, Claus R, Deigner HP, et al. Modified low densitylipoprotein delivers substrate for ceramide formation and stimulatesthe sphingomyelin-ceramide pathway in human macrophages. FEBS Lett 1997; 405: 55-9.
138. Morita SY, Nakano M, Sakurai A, Deharu Y, Vertut-Doi A, Handa T. Formation of ceramideenriched domains in lipid particles enhancesthe binding of apolipoprotein E. FEBS Lett 2005; 579: 1759-64.
139. Morita SY, Kawabe M, Sakurai A, et al. Ceramide in lipid particlesenhances heparan sulfate proteoglycan and low density lipoproteinreceptor-related proteinmediated uptake by macrophages. J BiolChem 2004; 279: 24355-61.
140. Byfield FJ, Tikku S, Rothblat GH, Gooch KJ, Levitan I. OxLDLincreases endothelial stiffness, force generation, and network formation. J Lipid Res 2006; 47: 715-23.
141. Feron O, Michel JB, Sase K, Michel T. Dynamic regulation ofendothelial nitric oxide synthase: complementary roles of dual acylationand caveolin interactions. Biochemistry 1998; 37: 193-200.
142. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidizedlow density lipoprotein displaces endothelial nitric-oxide synthase(eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 1999; 274: 32512-9.
143. Chikani G, Zhu W, Smart EJ. Lipids: potential regulators of nitricoxide generation. Am J Physiol Endocrinol Metab 2004; 287: E386-E389.
144. Dumitru CA, Zhang Y, Li X, Gulbins E. Ceramide: a novel playerin reactive oxygen speciesinduced signaling? Antioxid Redox Signal 2007; 9: 1535-40.
145. Morgan MJ, Kim YS, Liu Z. Lipid rafts and oxidative stressinducedcell death. Antioxid Redox Signal 2007; 9: 1471-83.
146. Levitan I, Gooch KJ. Lipid rafts in membrane-cytoskeleton interactionsand control of cellular biomechanics: actions of oxLDL. AntioxidRedox Signal 2007; 9: 1519-34.
147. Chun M, Liyanage UK, Lisanti MP, Lodish, HF. Signal transductionof a G protein-coupled receptor in caveolae: colocalization ofendothelin and its receptor with caveolin. Proc Natl Acad Sci USA 1994; 91, 11728-32.
148. De Weerd WF, Leeb-Lundberg LM. Bradykinin sequesters B2bradykinin receptors and the receptorcoupled G alpha subunits Galpha q and G alpha i in caveolae in DDT1MF-2 smooth musclecells. J Biol Chem 1997; 272, 17858-66.
149. Feron O, Smith TW, Michel T, Kelly RA. Dynamic targeting of theagonist-stimulated m2 muscarinic acetylcholine receptor to caveolaein cardiac myocytes. J Biol Chem 1997; 272: 17744-8.
150. Schwencke C, Yamamoto M, Okumura S, Toya Y, Kim SJ, Ishikawa Y. Compartmentation of cyclic adenosine-monophosphatesignaling in caveolae. Mol Endocrinol 1999; 13: 1061-70.
151. Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res 2003; 44: 655-67.
152. Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrinindependentendocytic pathway in mammalian cells. Nat Cell Biol 2006; 8: 46-54.
153. Smart EJ, Graf GA, Mcniver MA, et al. Caveolins, liquid-ordereddomains, and signal transduction. Mol Cell Biol 1999; 19: 7289-304.
154. Mineo C, James GL, Smart EJ, Anderson RGW. Localization ofepidermal growth factor-stimulated Ras/Raf-1 interaction to caveolaemembrane. J Biol Chem 1996; 271: 11930-5.
155. Liu P, Ying Y, Ko YG, Anderson RGW. Localization of plateletderivedgrowth factor-stimulated phosphorylation cascade tocaveolae. J Biol Chem 1996; 271: 10299-303.
156. Tauchi T, Feng GS, Shen R, et al. SH2-containing phosphotyrosinephosphatase syp is a target of p210bcr-abl tyrosine kinase. J BiolChem 1994; 269: 15381-7.
157. Song SK, Li S, Okamoto T, Qi{dotless}illiam LA, Sargiacomo M, Lisanti MP. Co-purification and direct interaction of Ras with caveolin, anintegral membrane protein of caveolae microdomains. Detergentfreepurification of caveolae micro-domains. J Biol Chem 1996; 271: 9690-7.
158. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, afamily of scaffolding proteins for organizing 'preassembled signalingcomplexes' at the plasma membrane. J Biol Chem 1998; 273: 5419-22.
159. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosinekinase, EGF-R, with caveolins. Caveolin binding negativelyregulates tyrosine and serine/threonine kinase activities. J BiolChem 1997; 272, 30429-38.
160. Milligan G, Grassie MA, Wise A, Macewan DJ, Magee AI, Parenti M. G-protein palmitoylation: regulation and functional significance. Biochem Soc Trans 1995; 23, 583-7.
161. Shaul PW, Smart EJ, Robinson LJ, et al. Acylation targets endothelialnitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 1996; 271: 6518-22.
162. Mumby SM. Reversible palmitoylation of signaling proteins. CurrOpin Cell Biol 1997; 9: 148-54.
163. Song KS, Sargiacomo M, Galbiati F, Parenti M, Lisanti MP. Targetingof a G alpha subunit (Gi1 alpha) and c-Src tyrosine kinase tocaveolae membranes: clarifying the role of N-myristoylation. CellMol Biol 1997; 43: 293-303.
164. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid raftsand caveolae. Cell 2001; 106, 403-11.
165. Zacharias DA, Violin JD, Newton AC, Tsien RY. Partitioning oflipid-modified monomeric GFPs into membrane microdomains oflive cells. Science 2002; 296: 913-6.
166. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting theinteraction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997; 272, 25437-40.
167. Oka N, Yamamoto M, Schwencke C, et al. Caveolin interactionwith protein kinase C. Isoenzyme-dependent regulation of kinaseactivity by the caveolin scaffolding domain peptide. J Biol Chem 1997; 272: 33416-21.
168. Engelman JA, Chu C, Lin A, et al. Caveolin-mediated regulation ofsignaling along the p42/44 MAP kinase cascade in vivo. A role forthe caveolin-scaffolding domain. FEBS Lett 1998; 428: 205-11.
169. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitricoxidesynthase-caveolin regulatory cycle. J Biol Chem 1998; 273: 3125-8.
170. Toya Y, Schwencke C, Couet J, Lisanti MP, Ishikawa Y. Inhibitionof adenylyl cyclase by caveolin peptides. Endocrine 1998; 139: 2025-31.
171. Carman CV, Lisanti MP, Benovic JL. Regulation of G proteincoupledreceptor kinases by caveolin. J Biol Chem 1999; 274, 8858-64.
172. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolarfunction human disease. J Clin Invest 2001; 108: 1553-61.
173. Hnasko R, Lisanti MP. The biology of caveolae: lessons fromcaveolin knockout mice and implications for human disease. MolInterv 2003; 3: 445-64.
174. Razani B, Combs TP, Wang XB, et al. Caveolin-1-deficient miceare lean, resistant to diet-induced obesity, and show hypertriglyceridemiawith adipocyte abnormalities. J. Biol. Chem 2002; 277: 8635-47.
175. Razani B, Wang XB, Engelman JA, et al. Caveolin-2-deficientmice show evidence of severe pulmonary dysfunction without disruptionof caveolae. Mol. Cell. Biol 2002b; 22, 2329-44.
176. Schubert W, Frank PG, Woodman SE, et al. Microvascular hyperpermeabilityin caveolin-1 (-/-) knock-out mice: treatment with aspecific NOSinhibitor, L-NAME, restores normal microvascularpermeability in Cav-1 null mice. J Biol Chem 2002; 277: 40091-8.
177. Woodman SE, Park DS, Cohen AW, et al. Caveolin-3 knock-outmice develop a progressive cardiomyopathy and show hyperactivationof the p42/44 MAP kinase cascade. J Biol Chem 2002; 277: 38988-97.
178. Wang Y, Zeigler MM, Lam GK, et al. The role of the NADPHoxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survival. Am J Respir Cell Mol Biol 2007; 36: 68-77.
179. DeLeo FR, Quinn MT. Assembly of the phagocyte NADPH oxidase:molecular interaction of oxidase proteins. J Leukoc Biol 1996; 60: 677-91.
180. Bhatt NY, Kelley TW, Khramtsov VV, et al. Macrophagecolonystimulatingfactor-induced activation of extracellular-regulatedkinase involves phosphatidylinositol 3-kinase and reactive oxygenspecies in human monocytes. J Immunol 2002; 169: 6427-34.
181. Rajendran L, Simons K. Lipid rafts and membrane dynamics. JCell Sci 2005; 118: 1099-102.
182. Vilhardt F, van Deurs B. The phagocyte NADPH oxidase dependson cholesterol-enriched membrane microdomains for assembly. EMBO J 2004; 23: 739-48.
183. Grandl M, Bared SM, Liebisch G, Werner T, Barlage S, Schmitz G. E-LDL and Ox-LDL differentially regulate ceramide and cholesterolraft microdomains in human Macrophages. Cytometry A 2006; 69: 189-91.